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Abstract
Tumor hypoxia negatively regulates cell growth and causes a more malignant phenotype by increasing
the expression of genes encoding angiogenic, metabolic and metastatic factors. Of clinical importance,
insufficient tumor oxygenation affects the efficiency of chemotherapy and radiotherapy by poorly
understood mechanisms. The hypoxia-inducible factor (HIF)-1 is a master transcriptional activator of
oxygen-regulated genes and HIF-1 is constitutively upregulated in several tumor types. HIF-1 might
thus be implicated in tumor therapy resistance. We found that transformed mouse embryonic fibroblasts
deficient for HIF-1alpha are more susceptible to the treatment with carboplatin, etoposide and ionizing
radiation than wild-type cells. Increased cell death in HIF-1alpha-deficient cells was because of
apoptosis and did not involve p53 induction. Tumor chemotherapy of experimental fibrosarcoma in
immunocompromised mice with carboplatin and etoposide confirmed the enhanced susceptibility of
HIF-1alpha-deficient cells. Agents that did not cause DNA double-strand breaks, such as
DNA-synthesis inhibitors or a DNA single-strand break-causing agent equally impaired cell growth,
independent of the HIF-1alpha genotype. Functional repair of a fragmented reporter gene was decreased
in HIF-1alpha-deficient cells. Thus, hypoxia-independent basal HIF-1alpha expression in tumor cells, as
known from untransformed embryonic stem cells, is sufficient to induce target gene expression,
probably including DNA double-strand break repair enzymes.
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Abstract 
Tumor hypoxia negatively regulates cell growth and causes a more malignant 
phenotype by increasing the expression of genes encoding angiogenic, metabolic 
and metastatic factors. Of clinical importance, insufficient tumor oxygenation affects 
the efficiency of chemotherapy and radiotherapy by poorly understood mechanisms. 
The hypoxia-inducible factor (HIF)-1 is a master transcriptional activator of oxygen-
regulated genes and HIF-1 is constitutively upregulated in several tumor types. HIF-1 
might thus be implicated in tumor therapy resistance. We found that transformed 
mouse embryonic fibroblasts deficient for HIF-1α are more susceptible to the 
treatment with carboplatin, etoposide and ionizing radiation than wild-type cells. 
Increased cell death in HIF-1α-deficient cells was due to apoptosis and did not 
involve p53 induction. In contrast to these treatments, all of which cause DNA 
double-strand breaks, DNA synthesis-inhibitors or a DNA single-strand break-causing 
agent equally impaired cell growth, independent of the HIF-1α genotype. Tumor 
chemotherapy of experimental fibrosarcomas in immunocompromised mice with 
carboplatin and etoposide confirmed the in vitro results. As observed before in 
untransformed embryonic stem cells, hypoxia-independent basal HIF-1α expression 
in tumor cells is sufficient to affect target gene expression which might include DNA 
double-strand break repair enzymes. 
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Introduction 
Hypoxic microenvironments are frequently found in solid tumors as a result of 
morphologically and functionally inappropriate vascularization, irregular blood flow, 
anemia and high oxygen consumption of rapidly proliferating malignant cells. Tumor 
hypoxia is associated with malignant progression; resistance to chemotherapy, 
photodynamic therapy and radiotherapy; increased metastasis and poor prognosis 
(Brown and Giaccia, 1998; Höckel et al., 1999; Brown, 2000; Höckel and Vaupel, 
2001; Vaupel et al., 2001). Many of these effects in hypoxic tumor cells are mediated 
by oxygen-regulated transcriptional activation of a specific set of genes whose 
relation to therapy resistance is only poorly understood. 
 The hypoxia-inducible factor-1 (HIF-1) activates a number of oxygen-regulated 
genes critically involved in adaptation to hypoxia (Semenza, 2000; Wenger, 2002). 
HIF-1 is constitutively upregulated in many cancer types and plays a major role in 
tumor progression (Harris, 2002; Semenza, 2002). HIF-1 elevates vascular 
endothelial growth factor-dependent tumor angiogenesis and it mediates the 
increased glycolytic capacity of tumor cells, known as Warburg effect (Seagroves et 
al., 2001; Minchenko et al., 2002). HIF-1 is a α1β1 heterodimer specifically 
recognizing hypoxia response elements of oxygen-regulated genes (Wang et al., 
1995). Under normoxic conditions, the von Hippel-Lindau tumor suppressor protein 
(pVHL) targets the HIF-1α subunit for rapid ubiquitination and proteasomal 
degradation (Maxwell et al., 1999). pVHL binding requires oxygen-dependent prolyl 
hydroxylation of HIF-1α, representing the actual oxygen-sensing mechanism (Epstein 
et al., 2001; Ivan et al., 2001; Jaakkola et al., 2001).  
 The loss of tumor suppressors such as pVHL (Krieg et al., 2000), PTEN (Zundel 
et al., 2000) or p53 (Ravi et al., 2000), and oncogenes such as v-src (Jiang et al., 
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1997) have been shown to stabilize HIF-1α, which is overexpressed in the majority of 
human cancers (Zhong et al., 1999) with expression levels correlating with 
malignancy and negative survival prognosis (Birner et al., 2000; Aebersold et al., 
2001). Thus, as shown by the majority of published experimental tumor models, HIF-
1β (Jiang et al., 1997; Maxwell et al., 1997; Griffiths et al., 2002; Höpfl et al., 2002) as 
well as HIF-1α (Ryan et al., 1998; Kung et al., 2000; Ryan et al., 2000; Höpfl et al., 
2002; Williams et al., 2002) are positive factors for solid tumor growth. However, in 
one embryonic stem cell tumor model, HIF-1α-deficient (HIF-1α-/-) tumors have been 
shown to grow faster when compared with HIF-1α wild-type (HIF-1α+/+) tumors, 
apparently due to an increased rate of p53-dependent apoptosis in the HIF-1α+/+ cells 
(Carmeliet et al., 1998). The tumor suppressor protein p53 has been suggested to be 
induced by severe hypoxia (0.02% O2) and to cause apoptosis, resulting in a 
selective pressure against cells expressing wild-type p53 (Graeber et al., 1996). 
Unlike reported by others (An et al., 1998), we could not detect HIF-1α-dependent 
p53 stabilization under mild hypoxic (1% O2) conditions (Wenger et al., 1998). 
Indeed, several HIF-1-independent pathways have been shown to induce p53 under 
severely hypoxic conditions (Alarcón et al., 1999; Hammond et al., 2002).  
 Resistance to radiotherapy and chemotherapy in hypoxic tumor cells has been 
attributed to a multitude of mechanisms. These include direct effects through lowered 
generation of oxygen-dependent radical formation or decreased drug accessibility of 
the more distant hypoxic cells. Indirect effects include clonal selection for hypoxically 
adapted cells with altered transcriptome of proteome patterns (Brown, 2000; Vaupel 
et al., 2001). However, the precise molecular mechanisms underlying the therapy 
resistance of hypoxic cells are not fully understood. High HIF-1α expression levels in 
human squamous cell head-and-neck cancers are associated with incomplete 
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response to radiation and chemotherapy (Aebersold et al., 2001; Koukourakis et al., 
2002). We thus reasoned that intrinsic mechanisms, such as constitutive variations in 
the HIF-1α expression levels, might contribute to therapy resistance and analyzed 
whether HIF-1α mediates susceptibility to radiotherapy and chemotherapy. 
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Results  
Increased susceptibility of HIF-1α-deficient cells to chemotherapeutic agents 
Considerable evidence has been provided that HIF-1α is a positive factor for solid 
tumor growth. To analyze whether HIF-1α is also involved in chemotherapy 
resistance, we exposed wild-type mouse embryonic fibroblast (MEF)-HIF-1α+/+ and 
HIF-1α-deficient MEF-HIF-1α-/- cells for 48 hours to increasing concentrations of two 
clinically relevant chemotherapeutic agents, carboplatin and etoposide. To assess 
cellular toxicity of these agents, the MTT assay was employed, which is based on the 
functional activity of mitochondrial dehydrogenases in living cells, converting MTT to 
the colored formazan salt (Mosmann, 1983; Hansen et al., 1989). Interestingly, dose-
response curves were shifted to the left in MEF-HIF-1α-/- cells when compared to 
MEF-HIF-1α+/+ cells (Figure 1A). IC50 values for both agents were significantly 
(P=0.0313) lower in the HIF-1α-deficient cells, irrespective of whether the gas phase 
contained 20% or 1% oxygen (Figure 1B). The same elevated susceptibility could be 
observed with two subclones of the HIF-1α-deficient cell line, providing evidence that 
this was not due to clonal effects (data not shown).  
 
p53-Independent induction of apoptosis in HIF-1α-deficient cells after treatment with 
chemotherapeutic agents 
To assess the mode of increased cell death in HIF-1α-deficient MEF-HIF-1α-/- cells 
after treatment with the chemotherapeutic agents, DNA fragmentation was analyzed 
by agarose gel electrophoresis. Following treatment for 48 hours with 9 µM 
carboplatin or 0.4 µM etoposide, MEF-HIF-1α-/- but not MEF-HIF-1α+/+ cells showed 
the characteristic DNA laddering indicative for apoptotic DNA fragmentation (Figure 
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2A). Thus, the decreased viability in HIF-1α-deficient cells, as estimated with the 
MTT assay, might be due to increased apoptosis rather than growth arrest or 
necrosis. 
 One putative HIF-1α target responsible for the differential effects of the DNA-
damaging agents in HIF-1α-deficient and wild-type cells could be the tumor 
suppressor protein p53 that might be stabilized by a mechanism involving HIF-1α (An 
et al., 1998; Ravi et al., 2000). As shown by immunoblotting, relatively high p53 
protein levels are constitutively expressed in both cell lines independent of their HIF-
1α genotype (Figure 2B). Expression of the SV40 large T antigen in both cell lines, 
which is known to stabilize and inactivate p53 (Ali and DeCaprio, 2001), explains 
these relatively high levels of (non-functional) p53. However, these results imply that 
p53 does not mediate the HIF-1α-dependent differential susceptibility to 
chemotherapy. 
 
HIF-1α-deficiency does not affect cellular toxicity of iron chelators and a 
topoisomerase I inhibitor 
Carboplatin forms platinum-DNA adducts and etoposide is a topoisomerase II 
inhibitor, both of which result in DNA damage. We thus examined whether other toxic 
substances, which function through independent mechanisms, elicit the same 
differential HIF-1α-dependent responses. Therefore, the cells were treated with two 
iron chelators, deferoxamine and ciclopirox olamine, both of which are known to 
induce HIF-1α protein stability at low concentrations (Wanner et al., 2000). At higher 
concentrations, these iron chelators interfere with the cell cycle S phase, probably 
because of the inhibition of ribonucleotide reductase that produces 
deoxyribonucleoside triphosphates required for DNA synthesis. Iron chelators hence 
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display antiproliferative properties in tumor cells both in vitro and in clinical trials 
(Lederman et al., 1984; Farinelli and Greene, 1996; Gao and Richardson, 2001). 
Interestingly, the toxicity of the iron chelators under normoxic conditions was 
indistinguishable between the two cell lines, suggesting that the differential 
carboplatin and etoposide toxicity is due to specific mechanisms rather than due to a 
general vulnerability of the HIF-1α-deficient cells (Figure 3A). Of note, the iron 
chelators were less toxic in the HIF-1α-deficient cells under hypoxic conditions, which 
stands in sharp contrast to the results of carboplatin and etoposide treatment. 
Though the reason for this effect currently is unclear, it confirms the specificity of the 
carboplatin and etoposide effects and rules out gross variations in the general 
properties of the two cell lines. 
 Finally, the cells were treated for 48 hours with a topoisomerase I inhibitor, the 
camptothecin-derivative SN38. As shown in Figure 3B, the toxicity of SN38 was 
comparable in wild-type MEF-HIF-1α+/+ and HIF-1α-deficient MEF-HIF-1α-/- cells 
under both normoxic and hypoxic conditions. 
 
Increased susceptibility of HIF-1α-deficient cells to ionizing radiation 
Besides chemotherapy, radiotherapy is another tumor treatment modality known to 
be negatively affected by tumor hypoxia. We therefore treated the wild-type MEF-
HIF-1α+/+ and HIF-1α-deficient MEF-HIF-1α-/- cells with ionizing radiation doses from 
2 to 10 Gy and examined cellular viability 48 hours later. As shown in Figure 4, HIF-
1α-deficient MEF-HIF-1α-/- cells were significantly (P=0.0045) more susceptible to 
irradiaton when compared to wild-type cells, consistent with the inverse correlation 
between HIF-1α tumor expression and prognosis for the outcome of radiotherapy 
(Aebersold et al., 2001; Koukourakis et al., 2002).  
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Increased susceptibility of HIF-1α-deficient tumors to chemotherapy 
Immortalization and transformation of the wild-type MEF-HIF-1α+/+ and HIF-1α-
deficient MEF-HIF-1α-/- cells with the SV40 large T antigen and the H-ras oncogene 
provided a suitable cellular model for solid tumor formation (Ryan et al., 1998). 
Fibrosarcomas were generated by subcutaneous injection of these cells into 
immunocompromised athymic nu/nu mice. As observed before (Ryan et al., 2000), 
the HIF-1α-deficient MEF-HIF-1α-/- tumors initially grew slower than the wild-type 
tumors, confirming that HIF-1α is a positive factor for solid tumor growth (data not 
shown). Chemotherapy of the tumors was started when an equal tumor size (100 
mm3) was reached. Figure 5 shows the development of the tumor size of carboplatin 
or etoposide treated mice in relation to the saline controls. Following treatment, the 
tumor size of both cell lines became smaller than the corresponding controls. The 
MEF-HIF-1α-/- tumors were significantly (P=0.037 and <0.0001, respectively) more 
sensitive to chemotherapy than the wild-type cells, confirming that HIF-1α expression 
negatively affects therapy efficiency. 
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Discussion 
The molecular mechanisms underlying the therapy resistance of hypoxic tumor 
regions have not yet been completely elucidated. Here, we demonstrated that MEF-
HIF-1α-/- cells are more susceptible to the treatment with carboplatin and etoposide 
than MEF-HIF-1α+/+ cells in vitro as well as in vivo. We provide evidence that this 
effect is specific and not due to clonal differences since HIF-1α positive and negative 
cells were equally sensitive to other cytotoxic drugs. What could be the nature of the 
HIF-1 target gene(s) responsible for this differential susceptibility? A recent report 
demonstrated that the multidrug resistance gene MDR1 is a HIF-1 target gene 
(Comerford et al., 2002). While increased MDR1 gene expression would explain 
resistance of the MEF-HIF-1α-/- cells to carboplatin and etoposide, it cannot explain 
the increased sensitivity to ionizing radiation of MEF-HIF-1α-/- cells. This finding 
provides evidence against MDR1 being the only HIF-1 target gene involved in 
susceptibility to tumor therapy. This conclusion was further confirmed by the finding 
that a topoisomerase I inhibitor, in contrast to the topoisomerase II inhibitor, does not 
show differential toxicity. Thus, is there a common mode of action between 
carboplatin, etoposide and ionizing radiation? Carboplatin forms platinum-DNA 
adducts, resulting in DNA inter- and intra-strand crosslinks, and etoposide is a 
topoisomerase II inhibitor. Both treatments result in DNA damage, mainly by double-
strand breaks. Also ionizing radiation leads to DNA double-strand breaks. On the 
contrary, the equally effective SN38 is a topoisomerase I inhibitor, preventing the 
religation of transient DNA single-strand breaks caused by topoisomerase I. 
Therefore, DNA repair pathways involved in DNA double-strand break repair likely 
include potential HIF-1 targets.  
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 In our experiments, differential susceptibility towards chemotherapeutic agents 
was found under both normoxic (20% O2) and hypoxic (1% O2) conditions. These 
hypoxic conditions are sufficient to strongly induce HIF-1α protein stabilization (Jiang 
et al., 1996; Jewell et al., 2001), but are probably not severe enough to confer direct 
resistance to these agents in vitro. Differential toxic effects in the two cell lines could 
be observed already under normoxic conditions, despite the high instability of HIF-1α 
protein in the wild-type cells. However, this is consistent with the finding that HIF-1α-
deficient embryonic stem cells (Iyer et al., 1998; Ryan et al., 1998) and HIF-1β-
deficient hepatoma cells (Gassmann et al., 1997) repeatedly display a decreased 
expression of HIF-1 target genes already under normoxic conditions, suggesting that 
normoxic basal levels of HIF-1α (normally not detectable by immunoblotting) are 
sufficient to confer increased target gene expression as well as increased resistance 
to chemotherapy. 
 In summary, our experiments suggest that oxygen availability affects tumor 
therapy efficacy not only by direct effects of severe hypoxia (anoxia), but there might 
also be genetic components involving altered HIF-1 and HIF-1 target gene 
expression in malignant cells. Clearly, an anti-HIF-1 strategy is required. The 
identification of small molecule inhibitors of HIF-1 (Rapisarda et al., 2002) and the 
finding that Hsp90 inhibitors of the ansamycin family strongly inhibit HIF-1 function 
(Isaacs et al., 2002; Katschinski et al., 2002; Mabjeesh et al., 2002) provide a first 
step towards a pharmacological anti-HIF-1 tumor therapy. In addition to the inhibition 
of tumor angiogenesis and tumor glycolysis, such a strategy, based on our study, 
should also improve the efficiency of classical tumor therapies. 
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Materials and Methods 
Chemicals 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), cis-
diammine(1,1-cyclobutanedicarbo-xylato) platinum (carboplatin), 4'-
desmethylepipodophyllotoxin 9-(4,6-O-ethylidene-β-D-glucopyranoside) (etoposide), 
deferoxamine mesylate (DFX), and ciclopirox olamine were purchased from Sigma 
(Taufkirchen, Germany). 7-ethyl-10-hydroxycamptothecin (SN38) was obtained from 
Pharmacia-Upjohn (Freiburg, Germany). For tumor chemotherapy, carboplatin 
(Carboplat®) and etoposide (Etopophos®) were purchased from Bristol (München, 
Germany). 
 
Cell culture 
Mouse embryonic fibroblasts (MEFs) were derived from mouse d 9.5 embryos, either 
wild-type (MEF-HIF-1α+/+) or deficient (MEF-HIF-1α-/-) for HIF-1α, immortalized with 
SV40 large T antigen and transformed with H-ras (Ryan et al., 2000; Seagroves et 
al., 2001). All cell lines were cultured in Dulbecco's modified Eagle's medium (high 
glucose) as described previously (Katschinski et al., 2002). Oxygen partial pressures 
in the hypoxic workstation (InVivO2-400, Ruskinn Technology, Leeds, UK) or in the 
incubator (Model 3319, Forma Scientific, Thermo Life Sciences, Egelsbach, 
Germany) were either 140 mm Hg (20% O2 vol/vol, normoxia) or 7 mm Hg (1% O2 
vol/vol, hypoxia). 
 
Cytotoxicity assays 
Cells were cultured in 96 well plates and allowed to attach for 6 to 12 hours before 
the drugs were added for 48 hours. Irradiation was performed with 10 MeV photons 
 
 
 
Oncogene, Manuscript (Full paper) Unruh et al., p. 13 
generated by a linear accelerator (Mevatron, Siemens Corp., Germany) at a dose 
rate of 3 Gy/minute. Cell proliferation/viability was assessed by the MTT assay as 
described (Mosmann, 1983; Hansen et al., 1989). Briefly, following treatment of the 
cells, the medium was replaced with fresh medium containing 1 mg/ml MTT and 
incubated for 2 hours at 37°C. One volume of 20% SDS, 50% N,N-
dimethylformamide was added and incubated overnight at 37°C. Absorbances at 570 
nm were determined in a 96-well photometer. For DNA laddering, non-confluent cells 
from one 150 cm2 petri dish were collected and the DNA was isolated and analyzed 
as described previously (Katschinski et al., 1999). Immunoblot analysis of p53 
expression was performed as reported before (Wenger et al., 1998). 
 
Experimental tumor chemotherapy 
Animal experiments were performed in strict accordance with the NIH Guide for the 
Care and Use of Laboratory Animals and were approved by the local Governmental 
Commission for the Care of Animals, Kiel, Germany (V252-72241.122-2). NMRI 
athymic male nude mice (nu/nu) were obtained from Mollegaard and Bomholtgard 
Breeding and Research Centre (Ry, Denmark). Non-confluent cells were treated with 
0.2% trypsin in PBS for 10 minutes at 37°C and collected using a cell scraper. Cells 
(107) in 250 µl PBS were injected s.c. into the hind leg of ether-anaesthetized mice. 
Tumor size was measured with a caliper every second day and the volume was 
estimated according to the formula: volume = length x width2 x π/6. When the tumor 
volume reached 100 mm3, 200 µl 0.9% NaCl containing or not containing carboplatin 
(30 mg/kg body weight) or etoposide (10 mg/kg body weight) were injected into the 
tail vein of ether-anaesthetized mice. The mice were euthanized when the tumors 
reached a volume of >1 cm3. 
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Statistical analysis 
Drug concentrations causing 50% reduction of maximal MTT conversion (IC50 
values) were determined from sigmoidal dose-response curve fittings of each 
experiment using GraphPad Prism 3.0 software (GraphPad Software, San Diego, 
CA). Statistical analysis of IC50 values was performed using two-tailed Wilcoxon 
matched pairs test. Statistical analysis of irradiated cells and tumor volume 
regression was performed using two-tailed paired t-tests. P values <0.05 were 
considered statistically significant. 
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Figure Legends 
 
Figure 1 Differential susceptibility of wild-type MEF-HIF-1α+/+ and HIF-1α-deficient 
MEF-HIF-1α-/- cells to treatment with the chemotherapeutic agents carboplatin and 
etoposide. (A) The cells were treated with the indicated concentrations of carboplatin 
and etoposide for 48 hours under normoxic or hypoxic conditions. Cellular viability 
was quantified using the MTT assay. Maximal MTT conversion activity corresponded 
to 0% toxicity and was determined in solvent-treated cells (0 µM, not shown in the 
logarithmic scale). (B) Comparison of IC50 values between MEF-HIF-1α+/+ and MEF-
HIF-1α-/- cells. Asteriks indicate statistical significant differences (P=0.0313, Wilcoxon 
matched pairs test). (A and B) Shown are mean values ± SEM of n=6 independent 
experiments, each performed in triplicates 
 
Figure 2 Increased susceptibility of HIF-1α-deficient cells to chemotherapeutic 
agents is due to increased rate of apoptosis and does not involve p53 induction. (A) 
Apoptotic DNA fragmentation in MEF-HIF-1α-/- but not in MEF-HIF-1α+/+ cells. After 
treatment of the cells for 48 hours with the indicated concentrations of carboplatin 
and etoposide, total cellular DNA was isolated and analyzed by agarose gel 
electrophoresis and ethidium bromide staining. (B) Constitutive expression of p53 in 
the SV40 large T antigen-transformed MEF-HIF-1α+/+ and MEF-HIF-1α-/- cells. 
Immunoblot analysis of 75 µg protein extract derived from MEFs treated for 6 hours 
with 200 µM deferoxamine (DFX), 134 µM carboplatin (C-Pt) or solvent (Ctrl) 
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Figure 3 Similar susceptibility of wild-type MEF-HIF-1α+/+ and HIF-1α-deficient MEF-
HIF-1α-/- cells to treatment with the iron chelators deferoxamine and ciclopirox 
olamine (A) and the topoisomerase I inhibitor SN38 (B). Cellular toxicity was 
estimated as described for Figure 1A (shown as mean values ± SEM, n=3 
independent experiments, each performed in triplicates) 
 
Figure 4 Differential susceptibility of wild-type MEF-HIF-1α+/+ and HIF-1α-deficient 
MEF-HIF-1α-/- cells to irradiation (P=0.0045, paired t-test). Cellular toxicity was 
estimated as described for Figure 1A (shown as mean values ± SEM, n=3 
independent experiments, each performed in 12 dishes simultaneously) 
 
Figure 5 Differential efficacy of tumor chemotherapy of fibrosarcomas generated by 
subcutaneous injection of 107 wild-type MEF-HIF-1α+/+ and HIF-1α-deficient 
MEF-HIF-1α-/- cells into nude mice. The tumor size is shown as relative volumes 
between chemotherapy and saline control-treatments (mean values ± SEM). 
MEF-HIF-1α-/- cells were significantly more sensitive than MEF-HIF-1α+/+ cells: 
carboplatin, P=0.037, n=6 for both cell lines; etoposide, P<0.0001, n=8 for both 
cell lines (paired t-test) 
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